| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/12/2006 | CN1250246C Medicinal mixture possessing alpha glycocidase inhibiting activity and its use |
| 04/12/2006 | CN1250244C Composition for preventing and treating hyperlipidemia |
| 04/12/2006 | CN1250240C Isatis root extract, and preparing method and use thereof |
| 04/12/2006 | CN1250236C Application of cotton total flavone for preparing medicine of antithrombotic |
| 04/12/2006 | CN1250235C Anti-protozoon saponins |
| 04/12/2006 | CN1250229C Transdermic administrated external-use medicine composition |
| 04/12/2006 | CN1250228C Orally disintegrating tablet of pseuto-ginseng total saponins and its preparation |
| 04/12/2006 | CN1250227C Aminoglucose hydrochloride medicinal composition |
| 04/12/2006 | CN1250226C Pharmaceutical combination comprising either (S)-20ethoxy-3-[4-(2-{4-methane sulfonyl oxyphenyl} ethoxy) phenyl] propanoic acid or 3-{4-[2-(4-tboc amino-phenyl)ethoxy]phenyl}-(S)-2-ethoxy propionic ac |
| 04/12/2006 | CN1250225C Use of 2alpha-methyl-19-nor-20(s)-1alpha, 25-dihydroxyvitamin d3 to increase bone strength |
| 04/12/2006 | CN1250224C Theobromine with anticancer activity |
| 04/12/2006 | CN1250223C Pyrrolo-triazine and pyrimidine compounds |
| 04/12/2006 | CN1250222C Praziquantel composition for treating diseases due to sarcocystis, neospora, toxoplasma and isospora |
| 04/12/2006 | CN1250221C Treatment of female sexual dysfunction |
| 04/12/2006 | CN1250220C Use of central cannabinoid receptor antagonist for preparing medicines designed to facilitate smoking cessation |
| 04/12/2006 | CN1250219C Pharmaceutical composition |
| 04/12/2006 | CN1250218C Use of angiotensin II antagonists |
| 04/12/2006 | CN1250217C Bifendate oral disintegration tablet and its preparing process |
| 04/12/2006 | CN1250216C Medication for treating acute hepatitis and chronic hepatitis and preparation technique |
| 04/12/2006 | CN1250215C Carbamate compounds for use in preventing or treating bipolar disorder |
| 04/12/2006 | CN1250214C Carbamate compounds for use in preventing or treating bipolar disorder |
| 04/12/2006 | CN1250213C Carbamate compounds for use in preventing or treating nevous pain and cluster and migraine headache-associated pain |
| 04/12/2006 | CN1250212C Composition for improving lipids in blood |
| 04/12/2006 | CN1250211C Therapeutic and preventives agent containing cyclopentenone compounds as the active ingredient |
| 04/12/2006 | CN1250210C The use of sulfonylureas and sulphonyl thiourea derivative in preparation of anti diabetes drug |
| 04/12/2006 | CN1250209C Inhibitor for 20-hydroxy-eicosatetraenoic acid enzyme |
| 04/12/2006 | CN1250208C Fluoxetine enteric coated tablet |
| 04/12/2006 | CN1250207C 4, 4-diaryl butadienes compound and use of ultraviolet-ray filtering agent |
| 04/12/2006 | CN1250206C Adhesive patch |
| 04/12/2006 | CN1250205C Granular preparations for oral administration |
| 04/12/2006 | CN1250204C Physical stable spraying gel composition |
| 04/12/2006 | CN1250115C Use of lignan in foods |
| 04/12/2006 | CN1250097C Health-care and nutrient oil with functions of fatigue-resistance and lowering blood fat |
| 04/12/2006 | CA2484473A1 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea salt |
| 04/11/2006 | USRE39061 Pharmaceutical formulations comprising labdanes for the treatment of tumors or leukemias |
| 04/11/2006 | US7026516 Compounds with high monoamine transporter affinity |
| 04/11/2006 | US7026514 Compounds used to treat alcoholism |
| 04/11/2006 | US7026510 Inhibitors of the chemotactic activation induced by the fraction C5a of complement and from other chemotactic proteins (chemokines) that y activate a 7-transmembrane-domain receptor; psoriasis, rheumatoid arthritis, ulcerative colitis, acute respiratory distress syndrome, fibrosis; antiischemic agents |
| 04/11/2006 | US7026508 Succinate salt of O-desmethyl-venlafaxine |
| 04/11/2006 | US7026507 Method for the production of solid formulations of sodium 3-hydroxy-3-methylbutyrate |
| 04/11/2006 | US7026505 Method of treating tinnitus |
| 04/11/2006 | US7026501 Inhibitors of α4 mediated cell adhesion |
| 04/11/2006 | US7026500 Halogenated selective androgen receptor modulators and methods of use thereof |
| 04/11/2006 | US7026491 E.g., dimethylcarbamic acid, 2-oxo-3-benzyl-4-methyl-2H-1-benzopyran; affects both the Tumor Necrosis Factor alpha level and transcription activity of NuclearFactor kappa Beta; antiimmunoinflammatory agents and autoimmune properties; antiarthritis agents; rheummatic diseases; osteoporosis; leukemia |
| 04/11/2006 | US7026488 A hemeoxygenase inhibitory metalloprotoporphyrin derivative, especially Zn-protoporphyrin, conjugated with an amphipathic or water soluble polymer; anticarcinogenic agents with little side effect and excellent tumor accumulation; very potent and efficient; administered by intravenous injection; stability |
| 04/11/2006 | US7026487 Amines substituted with a dihydronaphthalenyl, chromenyl, or thiochromenyl group, a pyridyl group and an alkyl group, having retinoid-like biological activity |
| 04/11/2006 | US7026485 inhibitors of HIV protease; N-heterocyclic moiety containing hydroxyethylamine compounds where the heterocyclic moiety may be octahydroisoquinoline |
| 04/11/2006 | US7026484 For therapy of cancer |
| 04/11/2006 | US7026483 Forms of cabergoline |
| 04/11/2006 | US7026476 Intermediate arylamine compounds |
| 04/11/2006 | US7026475 carbapenem derivatives with an antibacterial activity |
| 04/11/2006 | US7026472 for example 1-(methylthio)-3-methoxy-4-(2-fluorophenyl)azetidin-2-one; induce neoplastic cell apoptosis or inhibit neoplastic cell proliferation |
| 04/11/2006 | US7026469 Compositions and methods of double-targeting virus infections and cancer cells |
| 04/11/2006 | US7026461 Engineered protein kinases which can utilize nucleotide triphosphate substrates |
| 04/11/2006 | US7026408 Sulphonated comb polymers and preparations, in particular hair cosmetic preparations, based on such sulphonated comb polymers |
| 04/11/2006 | US7026361 Dispersion stability; forming protective colloid; bioavailability; hypotensive agents, oral diseases |
| 04/11/2006 | US7026360 Pharmaceutical compositions containing compounds with activity for the enhancement of absorption of active ingredients |
| 04/11/2006 | US7026359 e.g., tridecafluoro-4,4-dimethyl-1-heptene trimer or 1H, 1H, 2H-perfluoro-1-octane trimer; causes little or no damage to the retina even when used over a long period. |
| 04/11/2006 | US7026358 Oral general anesthetics and metabolitically resistant anticonvulsants |
| 04/11/2006 | US7026357 Diphenylurea compounds |
| 04/11/2006 | US7026356 Fatty acid analogues for the treatment of diseases caused by the pathological proliferation of smooth muscle cells |
| 04/11/2006 | US7026355 Use of rhein or diacerhein compounds for the treatment or prevention of vascular diseases |
| 04/11/2006 | US7026354 Aromatic compositions for the inhibition of exoprotein production from gram positive bacteria |
| 04/11/2006 | US7026353 Inhibition of Gram positive bacteria |
| 04/11/2006 | US7026352 Physiologically active substances |
| 04/11/2006 | US7026351 Cyclic 1-(acyloxy)-alkyl prodrugs of GABA analogs, compositions and uses thereof |
| 04/11/2006 | US7026349 Sulfonamides |
| 04/11/2006 | US7026348 Antiinflammatory agents; sepsis shock; rheumatic diseases |
| 04/11/2006 | US7026347 Porphyrin-polyamine conjugates for cancer therapy |
| 04/11/2006 | US7026346 Anticancer agents |
| 04/11/2006 | US7026345 Resolution of 3-amino alkylnitriles |
| 04/11/2006 | US7026344 by administering the 5-lipoxygenase inhibitor zileuton or a salt thereof |
| 04/11/2006 | US7026343 Pharmacologic inhibition of Myc function |
| 04/11/2006 | US7026342 treating fibrotic lung diseases and fibrotic hypertrophy or fibrosis of prostate, liver, the pleura, pancreas or bowel wall with saturated and unsaturated azoles and salts, e.g., 3-[2-phenyl-2-oxoethyl]-4,5-dimethyl-thiazolium salt |
| 04/11/2006 | US7026339 Inhibitors of HCV NS5B polymerase |
| 04/11/2006 | US7026338 Pharmaceutical nitrones |
| 04/11/2006 | US7026337 Gel formulations of hydroxypyridone derivatives, which contain solvents and hydrophilic gel-forming agents make possible a high release of the active compound |
| 04/11/2006 | US7026336 4-pyridinylimidazol-2-ylhydrocarbyl amine, (thio)urea, carbamic acid or sulfonamide derivatives, e.g., (2-(4-(4-Chloro-3-methoxy-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl)-2-methyl-propyl)-carbamic acid tert-butyl ester; Raf kinase inhibitors for the treatment of neurotraumatic diseases |
| 04/11/2006 | US7026335 Melanocortin receptor ligands |
| 04/11/2006 | US7026334 Thiazolidine compounds and pharmaceutical compositions exhibiting thrombopoietin receptor agonism |
| 04/11/2006 | US7026333 Retroviral protease inhibitors |
| 04/11/2006 | US7026332 Treating obsessive-compulsive disorder, acute stress disorder, post traumatic stress disorder, social anxiety disorder, somatization disorder, specific social phobia, premenstrual dysphoric disorder, and other psychological disorders |
| 04/11/2006 | US7026331 Inhibitors of IkB kinase (I Kappa B Kinase); treating various diseases including asthma, osteoarthritis, rheumatoid arthritis, Alzheimer's disease, cancer, infections, and cardiac infarct |
| 04/11/2006 | US7026330 Administering mixtures of rapamycin and/or derivatives and interleukin antagonists, for prophylaxis of blood disorders; anticarcinogenic agents |
| 04/11/2006 | US7026329 Administering to a patient suffering from the pain an analgesic or sub-analgesic amount of a bimodally-acting opioid agonist such as morphine and an amount of nalmefene effective to enhance the analgesic potency |
| 04/11/2006 | US7026328 Heterocyclic compounds which inhibit leukocyte adhesion mediated by α4 integrins |
| 04/11/2006 | US7026327 2-etherified 4-fluoroalkyl-6-(p-sulfonylphenyl)pyrimidines,e.g., 2-(4-fluorophenoxy)-4-[4-(methylsulfonyl)phenyl]-6](trifluoromethyl)pyrimidine; treatment of the pain, fever and inflammation of variety of conditions and diseases |
| 04/11/2006 | US7026326 Substituted heterocyclic compounds and methods of use |
| 04/11/2006 | US7026325 pyrazinoylguanidine compounds, e.g., 4-{4-[N-(3,5-diamino-6-chloropyrazine-2-carbonyl)guanidino]butyl}-N-(2-aminoethyl)benzamide hydrochloride; are absorbed less rapidly from mucosal surfaces, especially airway surfaces; rehydration of mucosal surfaces; reducing blood pressure |
| 04/11/2006 | US7026324 Amide containing a pyridinone or pyrazinone compound as serine protease enzyme inhibitors |
| 04/11/2006 | US7026323 N-(naphth-2-ylaminocarbonylacetyl)- or N-(naphth-2-ylcarbonylamino- acetyl)- piperazine derivatives, e.g., 2-[((4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl)carbonyl]aminonaphthalene; useful as antithrombotic agents |
| 04/11/2006 | US7026322 Anticancer agents; fungicides |
| 04/11/2006 | US7026321 piperazine derivatives, e.g., (2R)-1-(2-methylbenzothiazol-5-yloxy)-3-[4-({5-[4-(trifluoromethyl)phenyl](4,5-dihydroisoxazol-3-yl)}methyl)piperazinyl]propan-2-ol; treating diabetes, arrhythmia, intermittent claudication, angina, congestive heart disease, and myocardial infarction |
| 04/11/2006 | US7026320 Serotonergic agents |
| 04/11/2006 | US7026319 Use of vitamin combination for the treatment of pruritus and non-infective disorders involving itching and/or inflammation |
| 04/11/2006 | US7026318 Compounds exhibiting X-type sPLA2 inhibiting effect |
| 04/11/2006 | US7026317 bind to corticotropin releasing factor (CRF) receptors; psychological disorders; anxiety-related disorders; central nervous system disorders |
| 04/11/2006 | US7026316 (optionally aza)cycloalkyl-N,N-optionally thia-, oxothia- or dioxothia-)alkyleneglycine derivatives, e.g., N-{4-[(1S)-1-amino-2-oxo-2-(1,3-thiazolidin-3-yl)ethyl]cyclohexyl}-N'-hexylureA; especially treating type 2 diabetes |
| 04/11/2006 | US7026315 synergistic mix of (1) C-carbonylamino-O-cycloalkylmethyl-2,3-dihalo-6-haloalkyl or haloalkoxy-benzaldehyde oximes and (2) N[3-(p-tert-butylphenyl-2-methylpropyl]-piperidine or -dimethylmorpholine or 4-alkyl-2,6-dimethylmorpholine; applying to plants, seeds, and soils |
| 04/11/2006 | US7026314 Psychological disorders, antidepressants, anxiolytic agents, eating disorders; serotonin receptors antagonist |